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Enteroviruses are thought to be etiologic agents in some 
cases of human myocarditis and dilated cardiomyopathy. 
Murine models of acute coxsackievirus 83 myocarditis 
implicate coxsackie B viruses as possible causes of human 
myocarditis. hdirect evidence implicating enteroviruses as 
causative agents in human heart disease derives from 
serologic studies. More recently, direct evidence for entero- 
viral presence in diseased homan heart tissues has been 
obtained by nucleic acid hybridization analyses. 
Advances in enteroviral molecular biology have promoted a 
renewed interest in the roles of enteroviruses in diseases 
beyond the paradigm of poliovirus as the etiologic agent of 
poliomyelitis. The enteroviruses are common human patho- 
gens and are etiologic agents in a wide variety of diseases 
(l-4). Here we discuss evidence for an etiologic link be- 
tween enteroviruses and human myocarditis and dilated 
(congestive) cardiomyopathy and apparent dilemmas in light 
of the well established murine coxsackievirus model and 
enteroviral biology. The reader is referred to several reviews 
of coxsackieviruses, viral myocarditis and picomavirus- 
induced diseases in general for perspective (l-8). 
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~though the data suggest that enterovir 
may be associated with 18% to 50% of cases 
or dilated cardiomyopathy, or both, causality 
established. Unanswered questions remain regarding the 
specific identity of the enteroviral genomes detected in the 
human heart and the potential for enteroviruses to persist 
in the heart. 
(J Am Co11 Cardioi 1990;15:1688-94) 
Limitation of human studies implicating viruses in myo- 
carditis. The primary evidence implicating enteroviruses as 
causative agents in some cases of human myocarditis derives 
from observations of increased enteroviral antibody titers, 
especially to members of the coxsackievirus group B (types 1 
to 6) serotypes among patients with myocarditis or patients 
who progress to chronic myocarditis or dilated cardiomyop 
athy, or both (2,4,6-16). Although such data are suggestive of 
an enteroviral etiology in some cases, it should be remem- 
bered that enteroviruses are common human pathogens and 
are frequently isolated (1,15,17). Diabetes mellitus (18) and 
amyotrophic lateral sclerosis (19,20) are human diseases that 
have been linked to enteroviral etiologies on the basis of 
circulating antibody titers or history of infection, but for 
which no viral etiology has been established. infection with 
one enterovirus can also boost antibody titers to other entero- 
viruses in a manner that is variable depending on the individ- 
ual (17). An additional limitation of human serologic studies 
implicating viruses in myocarditis rests with widely variable 
reports of acute and convalescent antibody titers and the lack 
of certainty that the actual time of acute ~~ect~o~ coincides 
with the onset of clinically evident heart dysfunction. 
Isolation of enteroviruses from human myocardium. Iso- 
lation of enteroviruses from heart tissues of patients with 
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the heart of a patient w 
under active research. 
determinants of the viru 
ond as yet undefin 
the disease process, 
on disease development. 
strains of mice are available for such studies, thereby 
itting experiments to identify ortant host genetic 
s. However, the mechanisms t-lying so~tr~b~t~o~s 
of gender, age and genetic makeup of the host to the 
induction and severity of disease are net clear. Currently, we 
cannot adequately extrapclate predictive genetic factors 
from murine models to hu an cardiac diseases. 
Nucleic acid hybridization is a standard technique for the 
detection and identification of specific genes and ribonucleic 
acid (RNA) transcripts from genes. The technique involves 
probe and target sequences, utilizing the fact that deoxyri- 
bonucleic acid (DNA) or RNA, or both, can form double- 
stranded (duplex or hybrid) molecules, each strand comple- 
mentary to the other by the rules of base pairing. The probe 
is generally a defined DNA or RNA sequence labeled with 
radioactivity or another type of reporter group for detection. 
Detection of eoteroviral RNA in a tissue provides direct 
proof of the presence of virus in sells (20) of the host, 
surpassing the inferential evidence of infection obtained 
thr gic st 
y. In an initial study (30) and a 
subsequent extension of this work (31). it was reported that 
coxsackievirus-specific sequences were detected using a 
coxsackievirus B2 probe in 9 (53%) of 17 or 14 (52%) of 27 
human hearts with histologically proved active or healing 
genomes of three cox- 
es have now bee 
resence of enteroviral 
w sensitive are such 
IQ6 viral RNA genomes 
irus were replicating less 
a cells contain about 1 x 
ell [42]), the assay would 
IO0 to 500 infected cells. 
enterovirus-infected cell per 200 to 1,000 ceils when approx- 
imately 100 cells are assayed. 
Hn situ h d~zati~~ assay. In situ hybridization applies 
nucleic acid hybridization to the detection of specific nucle- 
otide sequences in specific cells in tissue sections or cells 
from culture (43). Cells or sections are fixed and treated to 
make them accessible to the nucleic acid probe, then hybtid- 
izatiom is performed. Three studies (44-4~) recently 
reported using in situ hyb~dization robe human heart 
tissue for the presence of enteroviral 
Easton and Eglin (44) detected enteroviral 
(42%) of 12 biopsy samples from 
with clinical symptoms of myoc 
thors stated that coxsackievirus RNA was detected in hu- 
man heart tissues, this is misleading for the same reasons 
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described for the earlier investigations (30,31), which, in 
addition to these authors’ own data W), clearly demonstrate 
that the probe can hybridize to RNA from various other 
en’?roviruses. 
Another study (45) suggested that 26% to 25% of hearts 
from patients with myocarditis or dilated cardiomyopathy, 
respectively, were enterovirus infected. These investigators 
used a very well characterized probe consisting of essen- 
tiahy the entire coxsackievirus B3 genome. This probe was 
shown to be panenteroviral, detecting a variety of coxsackie 
B viruses and noncoxsackie B enteroviruses. Important 
control reactions in this study demonstrated that the positive 
signals observed in situ with the radioactive probe were 
virus specific and not due to hybridization artifacts. 
A recently completed study (46) assayed endomyocardial 
biopsy samples for the presence of enteroviral genomes 
using in situ hybridization. Seventeen frozen biopsy samples 
were sectioned then hybridized in situ with a well character- 
ized sequence from the 3’ half of the coxsackievirus B3 
genome, which shares significant homology with many en- 
teroviral genomes. Enteroviral RNA foci were detected in 3 
(18%) of the 17 samples. Two enteroviral RNA-positive 
hearts were myocarditic by histopathologic criteria (2 [25%1 
of 8 biopsy-positive hearts), and the third enterovirus- 
positive heart sample was biopsy-negative for myocarditis (I 
[II%] of 9 biopsy-negative hearts). The study employed 
infected and uninfected mouse heart controls to demonstrate 
that the probe was capable of detecting virus in heart tissue 
in foci dispersed throughout the myocardium. Cell culture 
controls, that is, cultures infected with various enterovi- 
ruses, demonstrated that the probe was able to detect many 
different enteroviruses. A bacterial plasmid vector probe 
control showed no hybridization with any target, thereby 
indicating that the results were virus specific. 
Implications of reported studies. Results from the five 
independent studies discussed previously, in which investi- 
gators used nucleic acid hybridization techniques to probe 
human heart tissues for viral RNA, provide the first compel- 
ling and direct evidence for the presence of enteroviral 
genomes in at least some human hearts with cardiomyopathy 
and myocarditis. The nucleic acid hybridization data suggest 
that 18% to 53% of patients with myocarditis may have a 
cardiac enteroviral infection. The actual percentage is un- 
clear because relatively few heart samples have been exam- 
ined. There is a wide discrepancy between interpretation of 
data and the cognate estimates of virus-positive hearts. Data 
from well controlled hybridization studies (45,46) suggest 
that about 18% to 25% of myocarditic and myopathic hearts 
may have enteroviral infections, although other workers 
(30,3W) have reported a much higher incidence of infec- 
tion (52% to 53%). These discrepancies may be due in part to 
differences in clinical diagnosis (47), as well as to difiefing 
PrevalenCeS Of eIIterOViNSes in local populations (4&49). 
strated that enteroviral infections may be found in human 
myocarditic and myopathic hearts. It is not clear how many 
individuals actually have a cardiac enteroviral infection at 
the time of clinical diagnosis of cardiac dysfunction; many 
more heart samples need to be assayed for the presence of 
viral genomes. More fundamentally important to the clini- 
cian and virologist alike, however, are intriguing questions 
that arise from the composite evidence implicating enterovi- 
nts in human heart disease. 
disease. Enteroviruses are common 
plicated as etiologic agents in many different diseases (l-4), 
and by adulthood most people have serum neutralizing 
antibodies to numerous enteroviruses (49,50). Antibody ti- 
ters to these viruses in adults are comparable to those 
present after vaccination against poliovirus, levels that are 
capable of conveying lifelong immunity from poliomyelitis. 
The humoral immune system is regarded as a major line of 
defense against viral infection (51,52) and against systemic 
enterovirus infection in particular. If we postulate that 
common enteroviruses are etiologic agents in some cases of 
human myocarditis, it must be determined how such viruses 
induce disease in the face of circulating neutralizing antibody 
in the majority of the population. One possibility is that 
reinfection with a common enterovirus occurs and tempo- 
rarily escapes neutralization to infect the heart. Reinfection 
with the same serotype of virus in the presence of neutral- 
izing antibody has been documented with other viruses 
(53-55), and this may occur more efficiently if the virus has 
drifted antigenically from the virus that caused the original 
infection. Infection with a variant enterovirus is illustrated 
by a recent outbreak of poliovirus in Finland with a pohovi- 
NS type 3 strain that had only a few antigenic differences 
from the vaccine type (56). An alternative possibility is 
infection by a relatively rare human enterovirus, one against 
which fewer individuals have neutralizing antibody. The 
isolation of echovirus 22 from a patient (25) with myocarditis 
suggests such a possibility. There are 69 classified human 
enteroviruses (I), and we are aware of no study in which 
rigorous screening has been done against these enteroviruses 
for immunoglobulm M (IgM) in sera of patients with myo- 
carditis. 
Immunosuppressive therapy for myoca 
fections. Clinical anecdote and trials on the ehicacy of 
cyclosporine in treatment of biopsy-proved myocarditis 
have so far been inconclusive (57,58), and the results of a 
large randomized study under way in the United States will 
not be available for another year at least, Studies of the 
effects of cyclosporine during experimental murine entero- 
viral infections raise an interesting question, however, it was 
shown (59) that the administration of cyclosporine to mice 
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Figure 1. Detection of enteroviral genomes with 
enzymatic amplification. A, E-l (Y-CACCGGAT- 
GGCCAATCCA) and E-2 (5’-TCCGGCCCCTGA- 
ATG) amplify common sequences within the 5’ 
nontranslated regions of coxsackievirus B3 and 
other sequenced enteroviruses to amplify a 195 
base pair fragment from all enterov:ral genomes 
sharing these primer sequences. B, 53-l (Y-GTTG- 
GACCCGGATGCGACCGG) and El-2 (Y-AACG- 
CTAGACAACACCCCATC) primersamplifya91 
base pair sequence within the capsid protein coding 
region of coxsackievirus 33 genomes specifically. 
Complementary DNA &DNA) was synthesized 
using reverse transcriptase, either E-l or 83-l as 
primer and enterovirus-infected cell RNA (0. I CLp) 
as template as described elsewhere (38). Pour 
percent of the cDNA reaction was amplified in a 50 
~1 polymerase chain reaction containing the appro- 
priate primer set as described elsewhere (66-68). 
Forty cyc!es were performed on a CetuslPerkin- 
Elmer Thermal Cycier, with each cycle pro- 
grammed as 5 s at w”C, I s at 50°C. Because of the 
lag times inherent in the heating block, sufficient 
time elapses during the heating step of each cycle 
for the rapid and processive Thermus aquaticus 
DNA polymerase (59) (CetuslPerkin-Elmer) to syn- 
thesize DNA fragments >l kilobase pair (kbp) in 
length (ST., unpublished observations). Ten mi- 
croliters from each polymerase chain reaction were 
electrophoresed in agarose gels. Lanes 1, coxsack- 
ievirus B3-M (a myocarditic strain in mice [27]); 2. 
coxsackievirus B3 (37); 3 to 5, human coxsackie- 
virus B3 isolates from 1956, 1963 and 1965, respec- 
tively (28); 6, coxsackievirus BI; 7, coxsackievirus 
A21; 8, poliovirus 3; 9, echo lrirus 30; 10, uninfected 
HeLa cell. DNA bands were visualized with ethid- 
ium bromide stain and ultraviolet hght illumination. 
The bromphenol blue dye front appears as a 
bleached area along the bottom of the gels. 
infected with coxsackievirus B3 resulted in more severe 
myocarditis and death in some cases, compared with control 
infected but untreated animals. Given that the serologic and 
hybridization data discussed previously suggest that patients 
with myocarditis have a significant likelihood of enteroviral 
infection of cardiac tissues, it seems consistent with the 
murine data to expect that administration of immunosup 
pressive drugs to patients with myocarditis would be dele- 
terious In one fifth to one half of cases; that is, cases in which 
enteroviral genomes were detected by hybridization in heart 
tissues. However, this has not been observed. 
Do enter&ruses persist ia cardiac tissue? Detection of 
enteroviral genomic RNA in cardiac tissues does not neces- 
sarily imply active infection. Some RNA viruses can gener- 
ate defective interfering particles that inhibit replication of 
standard infectious virus and thus aliow virus to persist at 
low, almost undetectable levels by infectivity assays (60). 
Thus, a focus of replicating virus and a defective interfering 
particle-inhibited viral infection might be detected by in situ 
A 8 
hybridization as similar, perhaps identical, entities. Al- 
though no definitive data exist that demonstrate the natural 
presence of defective interfering particles of enteroviruses in 
animals (61,62), cell culture models exist (63) and other 
picomaviruses (64,65) can persist for long periods in their 
host. 
There is a paucity of reports documenting isolation of 
infectious enteroviruscs directly from the heart (21-23,25). 
Persistence of an enterovirus as a result of a defective 
interfering particle mechanism would #be consistent with 
such few documented isolations. For an etiologic connection 
to be convincing, the virus must be isolated at the site of 
pathologic change rather than at a site remote from the 
lesion. Also, because enteroviruses are common human 
pathogens, isolation of viruses from throat washes or stool is 
not a demonstration of viral presence in the tissue of 
interest. Another explanation may be that some enterovi- 
ruses, notably those in the coxsackievirus A group, do not 
replicate well or at all in cell cultures used for detection of 
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enterovimses by clinical and research laboratories. COX- 
sa&evimses in group A have been generally overlooked 
because of this inherent difficulty. 
Will more sensitive molecular techniques answer such 
questions? Recent advances in molecular biology will make 
possible the identification of elusive quantities of the entero- 
viral genomic RNA in myocardial tissues. The polymerase 
chain reaction (66-68) is an enzymatic amplification tech- 
nique whereby very few copies of RNA or DNA sequences 
can be amplified more than a millionfold for molecular 
cloning, sequence analysis and hybridization studies. We 
have designed primers that, when used to prime complemen- 
tary DNA synthesis followed by enzymatic amplification, 
can be used to detect either a wide variety of enteroviruses 
(essentially panenteroviral) or, alternatively, specific geno- 
types such as coxsackievirus B3 isolates. To show the 
potential of this approach, lanes 1 to 5 (Fig. IA) demonstrate 
that primers specific for the coxsackievirus B3 genotype 
detect only coxsackievirus B3 isolates (two laboratory 
strains and three naturally occurring isolates from 1956,1%3 
and 1%5). When the same primers are used to detect other 
enteroviruses (Fig. IA, lanes 6 to 9), no DNA can be 
amplified, demonstrating the potential utility of genotype- 
specific primers for the polymerase chain reaction. Thus, 
detection and identification of specific enteroviral geno- 
types, which we had previously demonstrated for coxsack- 
ieviruses B3 and B4 by using dot blot hybridization ap- 
proaches (37,39), are probably possible using enzymatic 
amplification. Other primers were designed to detect a wide 
variety of enteroviral genomes based on homologous nucle- 
otide sequences in the highly conserved 5’ nontranslated 
region of the viral genome. Lanes I to 10 (Fig. IB) demon- 
strate that coxsackieviruses of both the B and A groups, 
polioviruses and echoviruses are detectable with such ge- 
neric primers. In each case, uninfected HeLa cell RNA was 
negative, demonstrating the specificity of the primers only 
for enteroviral sequences (lanes 10, Fig. IA and B). Enzy- 
matically amplified nucleotide sequences can be assayed by 
nucleic acid hybridization or by nucleotide sequence analy- 
sis (69). Thus, the technique of enzymatic nucleic acid 
sequence amplification should allow the specific identifica- 
tion of those viruses that have been detected by hybridiza- 
tion using generic enteroviral probes in heart biopsy samples 
(30,31&I-46). This approach is currently in use in our 
laboratories to identify and clone genomic sequences of 
human cardiotropic enteroviruses. 
Conclusions. Murine coxsackievirus B3 infection models 
demonstrate that an enterovirus call induce damage in the 
murine hear& for example, myocyte lysis and tissue necrosis 
with subsequent healing. Similar injury and repair are found 
in human hearts with myocaditis. Until relatively recently, 
serolosic data implicating enteroviruses as etioIo$c in myo- 
cadtis formed the basis for suspecting this connection in 
humans. The application of nucleic acid hybridization to the 
problem has provided the best evidence to date i 
the hypothesis that myocardial enteroviral iflfectio~ is etio- 
logically linked to at least some cases of human myocarditis 
and cardiomyopathy. However, studies discusse 
elr.ploying this approach have not identified any specific 
enterovirus in the heart and, because of the random nature of 
inflammatory myocardial disease and the e~domyocard~al 
biopsy, the real incidence ofenterovirus in diseased hearts is 
unclear. Unless the molecular techniques used to detect 
viruses are well controlled, potentially misreading data may 
be obtained about the identity of the viruses detected and the 
relative number of infected hearts. I~te~retatio~ of data 
must be considered iu the context of what we know about 
enteroviral biology and infectious diseases in gerleral. Ap- 
plication of molecular approaches such as enzymatic ampli- 
fication will help provide satisfactory answers to critical 
questions regarding enteroviral persistence in the heart, 
enteroviral identity and the interactions of enteroviruses and 
immunosuppressive agents with the host. 
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